Global Psoriasis Pipeline Drugs Market 2018 Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast to 2023 adds “Psoriasis Pipeline Drugs Market 2018 Global Analysis, Growth, Opportunities Research Report Forecasting to 2023”reports to its database

PUNE, INDIA, February 28, 2018 / — Psoriasis Pipeline Drugs Market:

Executive Summary

The report titled “Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023” presents the market potential of six major pipeline drugs meant for the treatment of Psoriasis. These six drugs that fall in the various categories of Injectables, Oral pills and Topical creams/lotions by mode of administration have been recognized as being clinically effective in Psoriasis treatment. Expected to be launched in the market within the next 4-5 years, these six potential drugs are likely to bring about major changes in the way psoriasis is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.

Over the recent years, the Psoriasis Drugs market is growing rapidly due to rising prevalence of Psoriasis patients around the world. Globally, the growth of Psoriasis Drugs market is driven by rising psoriatic population. The global psoriasis drugs market is projected to display a robust growth during 2019– 2023, chiefly driven by low efficacy and tolerability of present psoriasis drugs and improved safety and efficacy of investigational drugs.

The report has covered and analysed the major psoriasis drugs that are in pipeline and expected to be launched in the near future. The product profile, assessment of clinical trials, the regulatory phases and the potential of the drugs has been analysed in the report. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decision. The report titled “Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023” also analyzes the incidences of psoriasis in countries like United States, United Kingdom, France, Italy, Spain, Germany and Norway.

Request Sample Report @

Scope of the Report

Psoriasis Pipeline Drugs Assessment – Drug X1, X2, X3, X4, X5, X6 (Forecast Period: 2019-2023)

• Market Potential

• Clinical Trials

• Product Description

• Regulatory Phases

• 7Ps Analysis

Country Analysis – US, UK, France, Italy, Spain, Germany and Norway (Forecast Period: 2019-2023)

• Incidence of Psoriasis

Other Report Highlights

• Company Analysis – UCB, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim, Forward Pharma, Almirall and Valeant Pharmaceuticals

Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Content

1. Research Methodology

2. Psoriasis – An Overview 

3. Diagnosis of Psoriasis

4. Treatment of Psoriasis

5. Anti-Psoriasis Pipeline Drugs

6. Company Profiles 
    6.1. UCB 
    6.2. Sun Pharmaceutical Industries Ltd 
    6.3. Boehringer Ingelheim 
    6.4. Forward Pharma 
    6.5. Almirall 
    6.6. Valeant Pharmaceuticals

7. Number of Psoriasis Patients By Country 
    7.1. U.S 
    7.2. U.K 
    7.3. France 
    7.4. Italy 
    7.5. Germany 
    7.6. Norway

List of Figures


For further information on this report, visit –

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EIN Presswire